NPM1 and acute myeloid leukemia: We present an <i>NPM1</i>-mutated AML patient with an initial low ratio of <i>FLT3</i>-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse.